CSF2 and Decreased total granulocyte count: Granulocyte-macrophage colony-stimulating factor (GM-CSF) given subcutaneously (s.c.)is known to reduce the incidence and duration of severe granulocytopenia and to enhance the dose intensity of cytotoxic therapy by stimulating the proliferation and differentiation of haematopoietic progenitor cells as well as the functional activity of effector cells (Font et al, 1999).